Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $35.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 134.15% from the company’s current price. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q1 2027 earnings at ($0.95) EPS, Q2 2027 earnings at ($0.96) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($1.00) EPS and FY2027 earnings at ($3.89) EPS.

Several other equities analysts have also issued reports on CGEM. Wedbush boosted their price target on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. Wall Street Zen lowered Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 13th. BTIG Research reissued a “buy” rating and issued a $40.00 price target on shares of Cullinan Therapeutics in a research note on Friday, September 25th. Finally, TD Cowen upgraded Cullinan Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.71.

Cullinan Therapeutics Price Performance

Shares of Cullinan Therapeutics stock traded up $0.42 during midday trading on Friday, reaching $14.95. The company had a trading volume of 185,373 shares, compared to its average volume of 900,920. The stock has a fifty day moving average price of $19.56 and a 200 day moving average price of $16.73. The firm has a market cap of $962.05 million, a PE ratio of -4.82 and a beta of -0.04. Cullinan Therapeutics has a fifty-two week low of $5.68 and a fifty-two week high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). As a group, sell-side analysts forecast that Cullinan Therapeutics will post -3.08 EPS for the current year.

Insider Buying and Selling at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 30,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $20.26, for a total value of $607,800.00. Following the transaction, the insider directly owned 162,844 shares of the company’s stock, valued at approximately $3,299,219.44. This trade represents a 15.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 46,000 shares of company stock valued at $922,920 over the last 90 days. 8.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. AlphaCentric Advisors LLC grew its stake in shares of Cullinan Therapeutics by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 20,135 shares of the company’s stock worth $286,000 after acquiring an additional 1,094 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Cullinan Therapeutics during the 2nd quarter worth about $25,000. Allworth Financial LP lifted its holdings in Cullinan Therapeutics by 152.4% during the 2nd quarter. Allworth Financial LP now owns 2,893 shares of the company’s stock worth $53,000 after purchasing an additional 1,747 shares in the last quarter. Royal Bank of Canada lifted its holdings in Cullinan Therapeutics by 160.6% during the 1st quarter. Royal Bank of Canada now owns 4,044 shares of the company’s stock worth $58,000 after purchasing an additional 2,492 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Cullinan Therapeutics during the 2nd quarter worth about $53,000. Institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.